This clinical trial is focused on studying a condition known as Alpha-1 Antitrypsin Deficiency-Associated Liver Disease, which is a genetic disorder that can lead to liver damage. The study is investigating a treatment called Fazirsiran, also known by its code name TAK-999. Fazirsiran is a type of medication designed to target specific genes in the liver to help reduce the damage caused by this disease. The trial will compare the effects of Fazirsiran with a placebo to understand its safety and effectiveness, particularly in people with mild liver scarring, also known as fibrosis.

The main goal of the study is to evaluate the long-term safety of Fazirsiran, with a special focus on lung health, as the condition can also affect the lungs. Participants in the study will receive either Fazirsiran or a placebo through injections. The study will monitor various health indicators, including lung function and liver health, over a period of time to see how the treatment affects these areas. Participants will undergo regular check-ups and tests to track any changes in their condition.

This study is important for understanding how Fazirsiran can help people with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and to ensure that it is safe for long-term use. By participating in this trial, researchers hope to gather valuable information that could lead to better treatment options for those affected by this genetic disorder.